Cover Image
市場調查報告書

血友病:流行病學、患者為基礎的市場預測,治療流程,及上市藥、開發平台藥物分析

Hemophilia: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365167
出版日期 內容資訊 英文 474 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
血友病:流行病學、患者為基礎的市場預測,治療流程,及上市藥、開發平台藥物分析 Hemophilia: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年03月01日 內容資訊: 英文 474 Pages
簡介

本報告以血友病治療藥為焦點,提供銷售時期、期間帶給A型血友病、B型血友病的新長時間作用型治療藥的銷售額預測的影響,主要企業Biogen的登場對現有的大企業Bayer、Baxalta、CSL Behring、Novo Nordisk的市場佔有率的影響,及預防藥的治療擴大帶給血友病整體市場的規模的影響等相關分析。

預測:血友病

  • 摘要整理
  • 市場概要、趨勢
  • 調查手法、市場定義
  • Advate
  • Adynovate
  • Alprolix
  • BAX 817
  • BAY 94-9027
  • BeneFIX
  • CSL627
  • Eloctate
  • FEIBA
  • Idelvion
  • Ixinity
  • Kogenate/Helixate and Kovaltry
  • N8-GP
  • N9-GP
  • NovoEight
  • NovoSeven
  • Nuwiq
  • Rixubis
  • Vonvendi
  • Xyntha/ReFacto
  • 1次調查手法

治療:血友病

  • 摘要整理
  • 1次調查手法
  • 疾病定義、診斷
  • 患者區分
  • 目前治療選擇
  • 治療動態

流行病學:血友病

  • 摘要整理
  • 疾病的背景
  • 來源、手法
  • 預測:血友病
  • 預測:馮維勒布蘭德氏病
  • 流行病學者的考察
  • 能力與限制
  • 附錄

上市藥:血友病

  • 摘要整理
  • 產品概要
  • 後天性血友病的認證藥
  • 馮維勒布蘭德氏病的認證藥
  • 附錄
  • 產品簡介:Advate
  • 產品簡介:Adynovate
  • 產品簡介:Alprolix
  • 產品簡介:BeneFIX
  • 產品簡介:Eloctate
  • 產品簡介:FEIBA
  • 產品簡介:Idelvion
  • 產品簡介:Ixinity
  • 產品簡介:Kogenate FS
  • 產品簡介:NovoEight
  • 產品簡介:NovoSeven
  • 產品簡介:Rixubis
  • 產品簡介:Xyntha

開發平台:缺血性中風

  • 摘要整理
  • 臨床實驗平台概要
  • 標靶藥物簡介
  • 臨床實驗設計
  • 產品簡介 (後期階段) :BAX 817
  • 產品簡介 (後期階段) :BAY 94-9027
  • 產品簡介 (後期階段) :CSL627
  • 產品簡介 (後期階段) :CSL689
  • 產品簡介 (後期階段) :Kovaltry
  • 產品簡介 (後期階段) :LR769
  • 產品簡介 (後期階段) :N8-GP
  • 產品簡介 (後期階段) :N9-GP
  • 產品簡介 (後期階段) :emicizumab

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC12549

The treatment of hemophilia continues to evolve as more long-acting factor concentrates become available, making prophylactic therapy a more feasible approach.

This report addresses the following questions:

  • What impact will launch timing and duration of action have on the forecasted sales ofnew long-acting therapies for hemophilia A and hemophilia B?
  • What treatments are in development for hemophilia patients with inhibitors?
  • How will the emergence of Biogen as a key player in hemophilia impact the market shares of more established companies Bayer, Baxalta, CSL Behring, and Novo Nordisk?
  • What impact will the increased usage of prophylactic treatment have on the overall value of the hemophilia market?
  • How will the launch of Vonvendi, the first-in-class recombinant von Wille brand factor therapy, change treatment patterns in von Willebrand disease patients?

TABLE OF CONTENTS

FORECAST: HEMOPHILIA

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Methodology and Market Definition
  • 4. Advate
  • 5. Adynovate
  • 6. Alprolix, 7.BAX 817
  • 8. BAY 94-9027
  • 9. BeneFIX
  • 10. CSL627
  • 11. Eloctate
  • 12. FEIBA
  • 13. Idelvion
  • 14. Ixinity
  • 15. Kogenate/Helixate and Kovaltry
  • 16. N8-GP
  • 17. N9-GP
  • 18. NovoEight
  • 19. NovoSeven
  • 20. Nuwiq
  • 21. Rixubis
  • 22. Vonvendi
  • 23. Xyntha/ReFacto
  • 24. Primary Research Methodology

TREATMENT: HEMOPHILIA

  • 25. Executive Summary
  • 26. Primary Research Methodology
  • 27. Disease Definition and Diagnosis
  • 28. Patient Segmentation
  • 29. Current Treatment Options
  • 30. Treatment Dynamics

EPIDEMIOLOGY: HEMOPHILIA

  • 31. Executive Summary
  • 32. Disease Background
  • 33. Sources and Methodology
  • 34. Forecast: Hemophilia
  • 35. Forecast: Von Willebrand Disease
  • 36. Epidemiologist Insight
  • 37. Strengths and Limitations
  • 38. Appendix

MARKETED DRUGS: HEMOPHILIA

  • 39. Executive Summary
  • 40. Product Overview
  • 41. Products Approved for Acquired Hemophilia
  • 42. Products Approved for Von Willebrand Disease
  • 43. Appendix
  • 44. Product profile: Advate
  • 45. Product profile: Adynovate
  • 46. Product profile: Alprolix
  • 47. Product profile: BeneFIX
  • 48. Product profile: Eloctate
  • 49. Product profile: FEIBA
  • 50. Product profile: Idelvion
  • 51. Product profile: Ixinity
  • 52. Product profile: Kogenate FS
  • 53. Product profile: NovoEight
  • 54. Product profile: NovoSeven
  • 55. Product profile: Rixubis
  • 56. Product profile: Xyntha

PIPELINE: HEMOPHILIA

  • 57. Executive Summary
  • 58. Clinical Pipeline Overview
  • 59. Target Product Profile
  • 60. Clinical Trial Design
  • 61. Product profile (late stage): BAX 817
  • 62. Product profile (late stage): BAY 94-9027
  • 63. Product profile (late stage): CSL627
  • 64. Product profile (late stage): CSL689
  • 65. Product profile (late stage): Kovaltry
  • 66. Product profile (late stage): LR769
  • 67. Product profile (late stage): N8-GP
  • 68. Product profile (late stage): N9-GP
  • 69. Product profile (late stage): emicizumab

APPENDIX

  • 70. Appendix: Pipeline: Hemophilia
Back to Top